Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03967223
Title Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Solid Tumors
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors GlaxoSmithKline

synovial sarcoma


Cyclophosphamide + Fludarabine + NY-ESO-1-c259T

Age Groups: senior | child | adult
Covered Countries USA | ITA | FRA | ESP | CAN

No variant requirements are available.